DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Aldara (Imiquimod) - Published Studies

 
 



Aldara Related Published Studies

Well-designed clinical trials related to Aldara (Imiquimod)

Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. [2011.10]

Comparison of topical 3% diclofenac sodium gel and 5% imiquimod cream for the treatment of actinic keratoses. [2011.07]

Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. [2011.04]

Efficacy and safety of imiquimod versus podophyllotoxin in the treatment of anogenital warts. [2011.03]

Complete clearance is sustained for at least 12 months after treatment of actinic keratoses of the face or balding scalp via daily dosing with imiquimod 3.75% or 2.5% cream. [2011.02]

A randomized comparative study of tolerance and satisfaction in the treatment of actinic keratosis of the face and scalp between 5% imiquimod cream and photodynamic therapy with methyl aminolaevulinate. [2011.02]

Treatment of vulvar intraepithelial neoplasia with topical imiquimod: seven years median follow-up of a randomized clinical trial. [2011]

A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. [2010.09.24]

Effectiveness of cross polarized light and fluorescence diagnosis for detection of sub-clinical and clinical actinic keratosis during imiquimod treatment. [2010.07.01]

Comparative study on the efficacy, safety, and acceptability of imiquimod 5% cream versus cryotherapy for molluscum contagiosum in children. [2010.07]

Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). [2010.06.11]

The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. [2010.04.21]

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cycles. [2010.04]

Imiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cycles. [2010.04]

A double-blind, randomized controlled trial of the use of imiquimod cream for the treatment of anal canal high-grade anal intraepithelial neoplasia in HIV-positive MSM on HAART, with long-term follow-up data including the use of open-label imiquimod. [2010]

Topical imiquimod in conjunction with Nd:YAG laser for tattoo removal. [2009.11]

Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. [2009.10]

Treatment of keloid scars post-shave excision with imiquimod 5% cream: A prospective, double-blind, placebo-controlled pilot study. [2009.05]

Imiquimod 5% cream as adjunctive therapy for primary, solitary, nodular nasal basal cell carcinomas before Mohs micrographic surgery: a randomized, double blind, vehicle-controlled study. [2009.01]

Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. [2009.01]

Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts. [2008.07]

Treatment of vulvar intraepithelial neoplasia with topical imiquimod. [2008.04.03]

Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. [2008.04]

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. [2008.04]

A randomized parallel study to assess the safety and efficacy of two different dosing regimens of 5% imiquimod in the treatment of superficial basal cell carcinoma. [2008]

Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. [2007.12.06]

Efficacy of imiquimod as an adjunct to cryotherapy for actinic keratoses. [2007.11]

Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. [2007.11]

A phase III, randomized, open label study to evaluate the safety and efficacy of imiquimod 5% cream applied thrice weekly for 8 and 12 weeks in the treatment of low-risk nodular basal cell carcinoma. [2007.10]

Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. [2007.08]

Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. [2007]

Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: a randomized assessor-blind controlled trial. [2006.12]

An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. [2006.07]

Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): a randomized, double-blind, placebo-controlled trial. [2006.06]

Imiquimod-induced regression of actinic keratosis is associated with infiltration by T lymphocytes and dendritic cells: a randomized controlled trial. [2006.01]

Pilot study of imiquimod 5% cream as adjunctive therapy to curettage and electrodesiccation for nodular basal cell carcinoma. [2006.01]

Double-blind, randomized, placebo-controlled, prospective study evaluating the tolerability and effectiveness of imiquimod applied to postsurgical excisions on scar cosmesis. [2005.11]

Evaluation of imiquimod 5% cream to modify the natural history of herpes labialis: a pilot study. [2005.09.15]

Safety and efficacy of 5% imiquimod cream for the treatment of skin dysplasia in high-risk renal transplant recipients: randomized, double-blind, placebo-controlled trial. [2005.08]

Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. [2005.06]

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. [2005.05]

Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. [2005.04]

5% imiquimod cream and reflectance-mode confocal microscopy as adjunct modalities to Mohs micrographic surgery for treatment of basal cell carcinoma. [2004.12]

[Effects of imiquimod on latent human papillomavirus anal infection in HIV-infected patients] [2004.11]

Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. [2004.10]

Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosis. [2004.09]

Topical imiquimod 5% cream in external anogenital warts: a randomized, double-blind, placebo-controlled study. [2004.08]

Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial. [2004.08]

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. [2004.05]

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. [2004.05]

Short-course therapy with imiquimod 5% cream for solar keratoses: a randomized controlled trial. [2003.11]

Topical imiquimod 5% cream as an effective treatment for external genital and perianal warts in different patient populations. [2003.02]

Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. [2002.12]

A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. [2002.11]

Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. [2002.10]

Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study. [2002.10]

Safety studies of topical imiquimod 5% cream on normal skin exposed to ultraviolet radiation. [2002.09.02]

Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. [2002.09]

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. [2002.09]

Imiquimod 5% cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. [2001.05]

Treatment of external genital warts in men using 5% imiquimod cream applied three times a week, once daily, twice daily, or three times a day. [2001.04]

Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. [2001.01]

Effect of food on the pharmacokinetics and bioavailability of oral imiquimod relative to a subcutaneous dose. [2000.10]

Treatment of external genital warts in men with imiquimod 2% in cream. A placebo-controlled, double-blind study. [2000.09]

Correlation between pretreatment levels of interferon response genes and clinical responses to an immune response modifier (Imiquimod) in genital warts. [2000.07]

A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. [1999.12.03]

Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. [1999.12]

Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. [1999.08]

A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. [1998.08]

Mechanism of action of imiquimod 5% cream in the treatment of anogenital warts. [1998.07.01]

Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study. [1998.07]

Treatment of molluscum contagiosum in males with an analog of imiquimod 1% in cream: a placebo-controlled, double-blind study. [1998.05]

Imiquimod, a patient-applied immune-response modifier for treatment of external genital warts. [1998.04]

Treatment of genital warts with an immune-response modifier (imiquimod). [1998.02]

Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. [1998.01]

Well-designed clinical trials possibly related to Aldara (Imiquimod)

Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine. [2010.03.11]

Novel multi-peptide vaccination in Hla-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. [2009.06.15]

Other research related to Aldara (Imiquimod)

Treatment of cervical intraepithelial neoplasia with topical imiquimod: a randomized controlled trial. [2012]

A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. [2012]

Imiquimod 5% cream as pretreatment of Mohs micrographic surgery for nodular basal cell carcinoma in the face: a prospective randomized controlled study. [2012]

Results of an investigator-initiated single-blind split-face comparison of photodynamic therapy and 5% imiquimod cream for the treatment of actinic keratoses. [2012]

Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. [2012]

Immunomodulation by imiquimod in patients with high-risk primary melanoma. [2012]

Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. [2011.09.15]

Imiquimod-induced TLR7 signaling enhances repair of DNA damage induced by ultraviolet light in bone marrow-derived cells. [2011.08.15]

Randomized clinical trial of imiquimod: an adjunct to treating cervical dysplasia. [2011.07.13]

Disseminated superficial actinic porokeratosis treated effectively with topical imiquimod 5% cream. [2011.07]

Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases. [2011.07]

Failure of extensive extramammary Paget disease of the inguinal area to clear with imiquimod cream, 5%: possible progression to invasive disease during therapy. [2011.06]

Imiquimod and lymphatic field clearance: a new hypothesis based on a remote immune action on skin cancer. [2011.06]

Treatment of giant Bowen's disease with sequential use of photodynamic therapy and imiquimod cream. [2011.06]

Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. [2011.06]

Evaluation of imiquimod for topical treatment of vaccinia virus cutaneous infections in immunosuppressed hairless mice. [2011.06]

Topical imiquimod treatment of aciclovir-resistant herpes simplex disease: case series and literature review. [2011.06]

Imiquimod 5% cream for the treatment of nasal lesion of metastatic renal cell carcinoma. [2011.05]

A prospective self-controlled phase II study of imiquimod 5% cream in the treatment of infantile hemangioma. [2011.05]

Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors. [2011.04]

Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection. [2011.03]

Imiquimod 3.75% cream applied daily to treat anogenital warts: combined results from women in two randomized, placebo-controlled studies. [2011]

Cryosurgery is more effective in the treatment of primary, non-superficial basal cell carcinomas when applied during and not prior to a five week imiquimod course: a randomized, prospective, open-label study. [2011]

Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma. [2011]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012